These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 1838450)

  • 1. Long-term immunologic tolerance induction in chimeric mice after bone marrow transplantation across major histocompatibility barriers: persistent or redeveloping immunologic responsiveness after prolonged survival.
    Sugiura K; Yasumizu R; Iwai H; Inaba MM; Toki J; Ogura M; Hara I; Good RA; Ikehara S
    Thymus; 1991 Nov; 18(3):137-53. PubMed ID: 1838450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of immunologic tolerance to host minor histocompatibility antigens following allogeneic bone marrow transplantation in mice.
    Perreault C; Allard A; Brochu S; Poupart C; Fontaine P; Bélanger R; Gyger M
    Bone Marrow Transplant; 1990 Aug; 6(2):127-35. PubMed ID: 2145050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow transplantation with T-cell-depleted grafts. II. Reconstitution of immunohemopoietic functions in lethally irradiated mice transplanted with unseparated or T-cell-depleted bone marrow grafts disparate at minor histocompatibility antigens.
    Leshem B; Tsuberi BZ; Lebendiker Z; Anafi-Ayalon M; Shalit M; Weiss L; Slavin S; Kedar E
    Transplantation; 1987 Jun; 43(6):814-7. PubMed ID: 2954282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term (>1 year) analyses of chimerism and tolerance in mixed allogeneic chimeric mice using normal mouse combinations.
    Hayashi H; Toki J; Zhexiong L; Sugiura K; Inoue K; Ikehara S
    Stem Cells; 2000; 18(4):273-80. PubMed ID: 10924093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of tolerance induction using triple chimeric mice: major histocompatibility complex-disparate thymus, hemopoietic cells, and microenvironment.
    Cui W; Hosaka N; Miyake T; Wang X; Guo K; Cui Y; Li Q; Song C; Feng W; Li Q; Takaki T; Nishida T; Inaba M; Ikehara S
    Transplantation; 2008 Apr; 85(8):1151-8. PubMed ID: 18431236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
    Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH
    J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
    Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
    Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
    Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST
    J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reconstitution of lymphoid tissues under the influence of a subclinical level of graft versus host reaction induced by bone marrow T cells or splenic T cell subsets.
    Hirano M; Arase H; Arase-Fukushi N; Ogasawara K; Iwabuchi K; Miyazaki T; Good RA; Onoé K
    Cell Immunol; 1993 Oct; 151(1):118-32. PubMed ID: 8402923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of tolerance to donor type and host type H-2 antigens following transplantation of allogeneic bone marrow in mice.
    Levite M; Reisner Y
    Bone Marrow Transplant; 1990 Jul; 6(1):37-44. PubMed ID: 2143954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a novel method to induce tolerance in adult mice across fully allogeneic (entire H-2 plus multiminor histocompatibility) antigen barriers, using supralethal irradiation followed by injection of syngeneic bone marrow cells plus (donor X recipient) F1 spleen cells.
    Tomita Y; Himeno K; Mayumi H; Tokuda N; Nomoto K
    Immunobiology; 1989 Jun; 179(2-3):214-29. PubMed ID: 2793203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of systemic and organ-specific autoimmune disease in mice by allogeneic bone marrow transplantation.
    Ikehara S; Nakamura T; Sekita K; Muso E; Yasumizu R; Ohtsuki H; Hamashima Y; Good RA
    Prog Clin Biol Res; 1987; 229():131-46. PubMed ID: 3299389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leucyl-leucine methyl ester treatment of donor cells permits establishment of immunocompetent parent----F1 chimeras that are selectively tolerant of host alloantigens.
    Thiele DL; Calomeni JA; Lipsky PE
    J Immunol; 1987 Oct; 139(7):2137-42. PubMed ID: 3309052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.